Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-03-23
Based on 507 first isolates · MED-A · Cystitis (lower UTI) · 2024-03-24 → 2025-03-23
Internal medicine A
Per-organism detail: MED-A urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 83 % (80 %–86 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (7 %), Pseudomonas aeruginosa (5 %), Klebsiella pneumoniae (4 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
86 %
96 %
n = 27
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
83 %
78 %
n = 27
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
81 %
93 %
n = 27
ciprofloxacin CIP
trend · Escherichia coli
79 %
96 %
n = 27
mecillinam MEC
trend · Escherichia coli lower UTI only
79 %
93 %
n = 27
ceftriaxone CRO
trend · Escherichia coli
79 %
93 %
n = 27
73 %
85 %
n = 27
trimethoprim TMP
trend · Escherichia coli lower UTI only
73 %
89 %
n = 27
47 %
59 %
n = 27
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
12 %
4 %
n = 27
5 %
4 %
n = 27
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
4 %
0 %
n = 27

Most likely organisms for this profile

Escherichia coli
58 %
Klebsiella pneumoniae
9 %
Enterococcus faecalis
9 %
Proteus mirabilis
7 %
Pseudomonas aeruginosa
5 %
Klebsiella oxytoca
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.